Immuneering (IMRX) executive compensation, 2026 proxy

Benjamin J. Zeskind, Ph.D., President and Chief Executive Officer, was paid $1.7M in 2025, down 15% from $1.9M the year before.

Filed
April 20, 2026
Annual meeting
June 11, 2026
Pay year
2025
Named executives
3
CEO total pay
$1.7M-15% vs prior year
CEO 2025 Bonus
$423,385Paid at 120% of target
CEO 2025 Option Awards
$579,504Grant date fair value
CEO Target Bonus Percentage
55%Expressed as percentage of base salary

How Ph.D. was paid

$1.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary39%Bonus25%Option awards35%All other compensation1%

Named executive officers

ExecutiveTotal
Benjamin J. Zeskind, Ph.D.President and Chief Executive Officer$1,660,612
Brett Hall, Ph.D.Chief Scientific Officer$1,289,504
Michael D. BookmanChief Legal Officer$890,362

What changed and why

  • $1.7MBenjamin J. Zeskind received a total compensation of $1,660,612 for 2025, decreasing from $1,945,092 in 2024.
  • $641KBase salary for the CEO increased to $641,493 effective January 1, 2025.
  • 120%Discretionary annual bonuses were paid at 120% of target based on 2025 company performance.
  • Equity compensation for named executive officers consisted solely of stock option awards.
  • $225MThe company raised $225 million in gross proceeds from private and public financings in 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.